RITSUKO KOMAKI to Dasatinib
This is a "connection" page, showing publications RITSUKO KOMAKI has written about Dasatinib.
Connection Strength
0.094
-
Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627). Neuro Oncol. 2015 Jul; 17(7):992-8.
Score: 0.094
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.